{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:48:04Z","timestamp":1785422884457,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,22]]},"DOI":"10.7759\/cureus.97521","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:55:52Z","timestamp":1763859352000},"source":"Crossref","is-referenced-by-count":2,"title":["The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants"],"prefix":"10.7759","author":[{"given":"Sastry","family":"Chamarthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Sushma","family":"Chamarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-92-22538","article-title":"Recovery of cytopathogenic agent from chimpanzees with coryza","volume":"92","author":"Morris JA","year":"1956","unstructured":"Morris JA, Blount RE Jr, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 1956, 92:544-9. 10.3181\/00379727-92-22538","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a119901","article-title":"Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA): isolation, properties and characterization","volume":"66","author":"Chanock R","year":"1957","unstructured":"Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA): isolation, properties and characterization. Am J Hyg. 1957, 66:281-90. 10.1093\/oxfordjournals.aje.a119901","journal-title":"Am J Hyg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(76)80918-3","article-title":"Respiratory syncytial virus infections in infants: quantitation and duration of shedding","volume":"89","author":"Hall CB","year":"1976","unstructured":"Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr. 1976, 89:11-5. 10.1016\/s0022-3476(76)80918-3","journal-title":"J Pediatr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad010","article-title":"Respiratory syncytial virus infection: old challenges and new approaches","volume":"228","author":"Ramilo O","year":"2023","unstructured":"Ramilo O, Rodriguez-Fernandez R, Mejias A. Respiratory syncytial virus infection: old challenges and new approaches. J Infect Dis. 2023, 228:4-7. 10.1093\/infdis\/jiad010","journal-title":"J Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01012-2","article-title":"Differences between RSV A and RSV B subgroups and implications for pharmaceutical preventive measures","volume":"13","author":"Nuttens C","year":"2024","unstructured":"Nuttens C, Moyersoen J, Curcio D, et al.. Differences between RSV A and RSV B subgroups and implications for pharmaceutical preventive measures. Infect Dis Ther. 2024, 13:1725-42. 10.1007\/s40121-024-01012-2","journal-title":"Infect Dis Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li Y","year":"2022","unstructured":"Li Y, Wang X, Blau DM, et al.. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022, 399:2047-64. 10.1016\/S0140-6736(22)00478-0","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100829","article-title":"Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination","volume":"38","author":"Hodgson D","year":"2024","unstructured":"Hodgson D, Wilkins N, van Leeuwen E, et al.. Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination. Lancet Reg Health Eur. 2024, 38:100829. 10.1016\/j.lanepe.2023.100829","journal-title":"Lancet Reg Health Eur"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall CB","year":"2009","unstructured":"Hall CB, Weinberg GA, Iwane MK, et al.. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009, 360:588-98. 10.1056\/NEJMoa0804877","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac155","article-title":"Respiratory syncytial virus burden and healthcare utilization in United States infants <1 year of age: study of nationally representative databases, 2011-2019","volume":"226","author":"Suh M","year":"2022","unstructured":"Suh M, Movva N, Jiang X, Reichert H, Bylsma LC, Fryzek JP, Nelson CB. Respiratory syncytial virus burden and healthcare utilization in United States infants &lt;1 year of age: study of nationally representative databases, 2011-2019. J Infect Dis. 2022, 226:S184-94. 10.1093\/infdis\/jiac155","journal-title":"J Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7214a1","article-title":"Seasonality of respiratory syncytial virus: United States, 2017-2023","volume":"72","author":"Hamid S","year":"2023","unstructured":"Hamid S, Winn A, Parikh R, et al.. Seasonality of respiratory syncytial virus: United States, 2017-2023. MMWR Morb Mortal Wkly Rep. 2023, 72:355-61. 10.15585\/mmwr.mm7214a1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13344","article-title":"Disease burden of RSV infections and bronchiolitis in young children (< 5 years) in primary care and emergency departments: a systematic literature review","volume":"18","author":"Heemskerk S","year":"2024","unstructured":"Heemskerk S, van Heuvel L, Asey T, Bangert M, Kramer R, Paget J, van Summeren J. Disease burden of RSV infections and bronchiolitis in young children (&lt; 5 years) in primary care and emergency departments: a systematic literature review. Influenza Other Respir Viruses. 2024, 18:e13344. 10.1111\/irv.13344","journal-title":"Influenza Other Respir Viruses"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-38919-1_13","article-title":"Live-attenuated respiratory syncytial virus vaccines","volume":"372","author":"Karron RA","year":"2013","unstructured":"Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013, 372:259-84. 10.1007\/978-3-642-38919-1_13","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120956","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","author":"Fulginiti VA","year":"1969","unstructured":"Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969, 89:435-48. 10.1093\/oxfordjournals.aje.a120956","journal-title":"Am J Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths C","year":"2017","unstructured":"Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev. 2017, 30:277-319. 10.1128\/CMR.00010-16","journal-title":"Clin Microbiol Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.99.3.e7","article-title":"Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database","volume":"99","author":"Law BJ","year":"1997","unstructured":"Law BJ, Wang EE, MacDonald N, et al.. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics. 1997, 99:E7. 10.1542\/peds.99.3.e7","journal-title":"Pediatrics"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(96)00137-0","article-title":"Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection","volume":"49","author":"Ohmit SE","year":"1996","unstructured":"Ohmit SE, Moler FW, Monto AS, Khan AS. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. J Clin Epidemiol. 1996, 49:963-7. 10.1016\/0895-4356(96)00137-0","journal-title":"J Clin Epidemiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.8.6922-6928.1998","article-title":"Antigenic structure of human respiratory syncytial virus fusion glycoprotein","volume":"72","author":"L\u00f3pez JA","year":"1998","unstructured":"L\u00f3pez JA, Bustos R, Orvell C, Berois M, Arbiza J, Garc\u00eda-Barreno B, Melero JA. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol. 1998, 72:6922-8. 10.1128\/JVI.72.8.6922-6928.1998","journal-title":"J Virol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan JS","year":"2011","unstructured":"McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011, 85:7788-96. 10.1128\/JVI.00555-11","journal-title":"J Virol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan JS","year":"2013","unstructured":"McLellan JS, Chen M, Leung S, et al.. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013, 340:1113-7. 10.1126\/science.1234914","journal-title":"Science"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0023","article-title":"Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis","volume":"6","author":"Sun M","year":"2023","unstructured":"Sun M, Lai H, Na F, et al.. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis. JAMA Netw Open. 2023, 6:e230023. 10.1001\/jamanetworkopen.2023.0023","journal-title":"JAMA Netw Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2017.1338567","article-title":"Respiratory syncytial virus: prospects for new and emerging therapeutics","volume":"11","author":"Jorquera PA","year":"2017","unstructured":"Jorquera PA, Tripp RA. Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Rev Respir Med. 2017, 11:609-15. 10.1080\/17476348.2017.1338567","journal-title":"Expert Rev Respir Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7432a3","article-title":"Use of clesrovimab for prevention of severe respiratory syncytial virus-associated lower respiratory tract infections in infants: recommendations of the advisory committee on immunization practices: United States, 2025","volume":"74","author":"Moulia DL","year":"2025","unstructured":"Moulia DL, Link-Gelles R, Chu HY, et al.. Use of clesrovimab for prevention of severe respiratory syncytial virus-associated lower respiratory tract infections in infants: recommendations of the advisory committee on immunization practices: United States, 2025. MMWR Morb Mortal Wkly Rep. 2025, 74:508-14. 10.15585\/mmwr.mm7432a3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa951","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","volume":"73","author":"Sim\u00f5es EA","year":"2021","unstructured":"Sim\u00f5es EA, Forleo-Neto E, Geba GP, et al.. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin Infect Dis. 2021, 73:e4400-8. 10.1093\/cid\/ciaa951","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.03.017","article-title":"The journey to a respiratory syncytial virus vaccine","volume":"125","author":"Mejias A","year":"2020","unstructured":"Mejias A, Rodr\u00edguez-Fern\u00e1ndez R, Oliva S, Peeples ME, Ramilo O. The journey to a respiratory syncytial virus vaccine. Ann Allergy Asthma Immunol. 2020, 125:36-46. 10.1016\/j.anai.2020.03.017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial","volume":"145","author":"Sim\u00f5es EA","year":"2025","unstructured":"Sim\u00f5es EA, Pahud BA, Madhi SA, et al.. Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial. Obstet Gynecol. 2025, 145:157-67. 10.1097\/AOG.0000000000005816","journal-title":"Obstet Gynecol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311183292102","article-title":"Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children","volume":"329","author":"Groothuis JR","year":"1993","unstructured":"Groothuis JR, Simoes EA, Levin MJ, et al.. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993, 329:1524-30. 10.1056\/NEJM199311183292102","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013757.pub3","article-title":"Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children","volume":"7","author":"Garegnani L","year":"2025","unstructured":"Garegnani L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2025, 7:CD013757. 10.1002\/14651858.CD013757.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e318220a553","article-title":"A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease","volume":"70","author":"Feltes TF","year":"2011","unstructured":"Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011, 70:186-91. 10.1203\/PDR.0b013e318220a553","journal-title":"Pediatr Res"},{"key":"ref29","article-title":"Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations","volume":"11","author":"Weisman LE","year":"2009","unstructured":"Weisman LE. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations. Curr Opin Mol Ther. 2009, 11:208-18.","journal-title":"Curr Opin Mol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale SB","year":"2023","unstructured":"Drysdale SB, Cathie K, Flamein F, et al.. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023, 389:2425-35. 10.1056\/NEJMoa2309189","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for prevention of RSV disease in healthy infants","volume":"393","author":"Zar HJ","year":"2025","unstructured":"Zar HJ, Sim\u00f5es EA, Madhi SA, et al.. Clesrovimab for prevention of RSV disease in healthy infants. N Engl J Med. 2025, 393:1292-303. 10.1056\/NEJMoa2502984","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13020175","article-title":"Nirsevimab prophylaxis for reduction of respiratory syncytial virus complications in hospitalised infants: the multi-centre study during the 2023-2024 season in Andalusia, Spain (NIRSEGRAND)","volume":"13","author":"Moreno-P\u00e9rez D","year":"2025","unstructured":"Moreno-P\u00e9rez D, Korobova A, Croche-Santander FB, et al.. Nirsevimab prophylaxis for reduction of respiratory syncytial virus complications in hospitalised infants: the multi-centre study during the 2023-2024 season in Andalusia, Spain (NIRSEGRAND). Vaccines (Basel). 2025, 13:175. 10.3390\/vaccines13020175","journal-title":"Vaccines (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1329426","article-title":"Clinical research on RSV prevention in children and pregnant women: progress and perspectives","volume":"14","author":"Gong X","year":"2023","unstructured":"Gong X, Luo E, Fan L, et al.. Clinical research on RSV prevention in children and pregnant women: progress and perspectives. Front Immunol. 2023, 14:1329426. 10.3389\/fimmu.2023.1329426","journal-title":"Front Immunol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00156-2","article-title":"Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study","volume":"25","author":"P\u00e9rez Marc G","year":"2025","unstructured":"P\u00e9rez Marc G, Vizzotti C, Fell DB, et al.. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study. Lancet Infect Dis. 2025, 25:1044-54. 10.1016\/S1473-3099(25)00156-2","journal-title":"Lancet Infect Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(25)00155-5","article-title":"Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study","volume":"9","author":"Williams TC","year":"2025","unstructured":"Williams TC, Marlow R, Cunningham S, et al.. Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study. Lancet Child Adolesc Health. 2025, 9:655-62. 10.1016\/S2352-4642(25)00155-5","journal-title":"Lancet Child Adolesc Health"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","year":"1998","unstructured":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998, 102.531-7. 10.1542\/peds.102.3.531","journal-title":"Pediatrics"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1067\/s0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes TF","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC, et al.. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003, 143:532-40. 10.1067\/s0022-3476(03)00454-2","journal-title":"J Pediatr"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin MP","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, et al.. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020, 383:415-25. 10.1056\/NEJMoa1913556","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2112186","article-title":"Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity","volume":"386","author":"Domachowske J","year":"2022","unstructured":"Domachowske J, Madhi SA, Sim\u00f5es EA, et al.. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022, 386:892-4. 10.1056\/NEJMc2112186","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060640","article-title":"Impact of nirsevimab immunization on pediatric hospitalization rates: a systematic review and meta-analysis (2024)","volume":"12","author":"Ricc\u00f2 M","year":"2024","unstructured":"Ricc\u00f2 M, Cascio A, Corrado S, et al.. Impact of nirsevimab immunization on pediatric hospitalization rates: a systematic review and meta-analysis (2024). Vaccines (Basel). 2024, 12:640. 10.3390\/vaccines12060640","journal-title":"Vaccines (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106624","article-title":"Sustained clinical and epidemiological impact of Respiratory Syncytial Virus (RSV) in young infants exposed to universal immunization with Nirsevimab at birth: an Italian multicenter, retrospective, cohort study 2024\/25","volume":"91","author":"Manzoni P","year":"2025","unstructured":"Manzoni P, Ricc\u00f2 M, Nobili C, et al.. Sustained clinical and epidemiological impact of Respiratory Syncytial Virus (RSV) in young infants exposed to universal immunization with Nirsevimab at birth: an Italian multicenter, retrospective, cohort study 2024\/25. J Infect. 2025, 91:106624. 10.1016\/j.jinf.2025.106624","journal-title":"J Infect"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106600","article-title":"Effectiveness of a targeted infant RSV immunization strategy (2024-2025): a multicenter matched case-control study in a high-surveillance setting","volume":"91","author":"Attaianese F","year":"2025","unstructured":"Attaianese F, Trapani S, Agostiniani R, et al.. Effectiveness of a targeted infant RSV immunization strategy (2024-2025): a multicenter matched case-control study in a high-surveillance setting. J Infect. 2025, 91:106600. 10.1016\/j.jinf.2025.106600","journal-title":"J Infect"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581970","article-title":"Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis","volume":"16","author":"Wang X","year":"2025","unstructured":"Wang X, Kong L, Liu X, Wu P, Zhang L, Ding F. Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis. Front Immunol. 2025, 16:1581970. 10.3389\/fimmu.2025.1581970","journal-title":"Front Immunol"},{"key":"ref44","unstructured":"Centers for Disease Control and Prevention (CDC). RSV vaccine guidance for pregnant women. (2025). Accessed: October 19, 2025: https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/pregnant-people.html."},{"key":"ref45","unstructured":"Centers for Disease Control and Prevention (CDC). RSV immunization guidance for infants and young children. (2025). Accessed: October 19, 2025: https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/infants-young-children.html."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.048397","article-title":"High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis","volume":"61","author":"Thorburn K","year":"2006","unstructured":"Thorburn K, Harigopal S, Reddy V, Taylor N, van Saene HK. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax. 2006, 61:611-5. 10.1136\/thx.2005.048397","journal-title":"Thorax"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3109\/23744235.2015.1082621","article-title":"Impact of bacteria in nasal aspirates on disease severity of bronchiolitis","volume":"48","author":"Jiang W","year":"2016","unstructured":"Jiang W, Wang T, Li L, Ji W, Wang Y, Yan Y. Impact of bacteria in nasal aspirates on disease severity of bronchiolitis. Infect Dis (Lond). 2016, 48:82-6. 10.3109\/23744235.2015.1082621","journal-title":"Infect Dis (Lond)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00148-6","article-title":"Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review","volume":"12","author":"Besteman SB","year":"2024","unstructured":"Besteman SB, Bogaert D, Bont L, Mejias A, Ramilo O, Weinberger DM, Dagan R. Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review. Lancet Respir Med. 2024, 12:915-32. 10.1016\/S2213-2600(24)00148-6","journal-title":"Lancet Respir Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500026","article-title":"Live-attenuated intranasal RSV vaccine in infants and toddlers","volume":"4","author":"Idoko OT","year":"2025","unstructured":"Idoko OT, Vargas SL, Bueso A, et al.. Live-attenuated intranasal RSV vaccine in infants and toddlers. NEJM Evid. 2025, 4:EVIDoa2500026. 10.1056\/EVIDoa2500026","journal-title":"NEJM Evid"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433395-the-evolving-landscape-of-respiratory-syncytial-virus-rsv-prophylaxis-in-infants","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:55:53Z","timestamp":1763859353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433395-the-evolving-landscape-of-respiratory-syncytial-virus-rsv-prophylaxis-in-infants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.97521","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,22]]}}}